US drugmaker AbbVie (NYSE: ABBV) has announced that priority review has been granted by the Japanese Ministry of Health, Labor and Welfare (MHLW) for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for the treatment of all major genotypes of the chronic hepatitis C virus (HCV).
This priority review follows European Medicines Agency (EMA) accelerated assessment and US Food and Drug Administration (FDA) priority review designations in December 2016 and January 2017 respectively.
AbbVie only submitted its new drug application for G/P in Japan last month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze